Academic literature on the topic 'Mieloproliferative'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Mieloproliferative.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Mieloproliferative"
Lozano, Teófilo, Carolina Wiesner, Rubén Mesa, Marie Emanuel Robyn, Martha Suárez, and Edgar Salguero. "Validação da Escala Abreviada de Sintomas em Pacientes com Neoplasias Mieloproliferativas (MPN-SAF-TSS): Avaliação em Pacientes Colombianos." Revista Ciencias de la Salud 15, no. 3 (October 5, 2017): 325. http://dx.doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.6116.
Full textNascimento, Hélio Mateus Silva, Even Herlany Pereira Alves, Wesley Rodrigues da Silva, John Arlley Sousa Pinho de Lira, Francisco Alex da Rocha Coelho, Paulo Roberto Carneiro Gomes, Julyanne Maria Saraiva de Sousa, et al. "Manifestações orais nas doenças mieloproliferativas: Uma revisão de literatura." Research, Society and Development 10, no. 5 (April 25, 2021): e0710514581. http://dx.doi.org/10.33448/rsd-v10i5.14581.
Full textPenalva Moreno, Maria Jose, Carolina Martinez-Laperche, Santiago Osorio Prendes, Elena Buces Gonzalez, Jose Luis Diez-Martin, and Ismael Buño Borde. "Calreticulin Mutations in JAK2-Negative Myeloproliferative Neoplasms. Experience in Our Center." Blood 124, no. 21 (December 6, 2014): 5586. http://dx.doi.org/10.1182/blood.v124.21.5586.5586.
Full textKrstanoska, F. "PO-01-044 Erectile dysfunction in oncosexology: Multiple myeloma, chronic lymphocytic leukemia and chronic mieloproliferative neoplasms." Journal of Sexual Medicine 16, no. 5 (May 2019): S60. http://dx.doi.org/10.1016/j.jsxm.2019.03.198.
Full textGalderisi, C., A. Cecilia, M. Tomaselli, P. Arcieri, L. Di Lullo, and P. Polito. "Quadro severo di mieloma multiplo e insufficienza renale trattato con successo con bortezomib e desametasone." Giornale di Clinica Nefrologica e Dialisi 22, no. 4 (January 31, 2018): 11–14. http://dx.doi.org/10.33393/gcnd.2010.1237.
Full textOlteanu, Ariela Ligia, Romeo-Gabriel Mihăilă, and Manuela Mihalache. "Evaluation of thrombin generation in classical Philadelphianegative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplasmele mieloproliferative Philadelphia- negative." Revista Romana de Medicina de Laborator 24, no. 3 (September 1, 2016): 279–89. http://dx.doi.org/10.1515/rrlm-2016-0026.
Full textArrieta López, Elizabeth, Stefanía Cruz Calderón, Juan David López Ponce de Leon, Fabián Emiliano Ahumada, Joaquín Rosales, and Mauricio Mejía González. "Miocarditis eosinofílica en paciente con síndrome hipereosinofílico primario con rearreglo genético del gen pdgfra/fip1l1." Revista Colombiana de Hematología y Oncología 8, Suplemento 1 (September 21, 2022): 66–67. http://dx.doi.org/10.51643/22562915.433.
Full textSánchez, Juan, Claudia Ricou, and Sandra Ponte. "Papel da equipa de enfermagem na consulta multidisciplinar a doentes com neoplasias mieloproliferativas." Onco.News, no. 38 (September 23, 2022): 24–28. http://dx.doi.org/10.31877/on.2019.38.04.
Full textGonzález García, C., C. Funes Vera, M. Blanquer Blanquer, and J. M. Moraleda Jiménez. "Síndromes mieloproliferativos." Medicine - Programa de Formación Médica Continuada Acreditado 11, no. 21 (November 2012): 1289–97. http://dx.doi.org/10.1016/s0304-5412(12)70452-3.
Full textFerré, O. J., and F. Sánchez-Guijo. "Síndromes mieloproliferativos." Medicine - Programa de Formación Médica Continuada Acreditado 12, no. 21 (November 2016): 1213–23. http://dx.doi.org/10.1016/j.med.2016.10.012.
Full textDissertations / Theses on the topic "Mieloproliferative"
Vener, C. "Caratteristiche morfologiche delle sindromi mieloproliferative croniche valutate su biopsie oesteomidollari." Doctoral thesis, Università degli Studi di Milano, 2009. http://hdl.handle.net/2434/54065.
Full textBaldazzi, Carmen <1980>. "Caratterizzazione Citogenetico-Molecolare delle alterazioni cromosomiche 3q26 e 1p36 nelle Sindromi Mieloproliferative." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2013. http://amsdottorato.unibo.it/5691/1/baldazzi_carmen_tesi.pdf.
Full textEVI1 and PRDM16 overexpression has been associated with poor prognosis in myeloid malignancies. The main mechanism is the rearrangement of chromosome bands 3q26 and 1p36, where they are mapped, respectively. Overexpression has also been reported in specific cytogenetic subgroups, without 3q26 and 1p36 abnormalities observable by chromosome banding analysis (CBA). The main aim of this study has been to identify and characterize EVI1 and PRDM16 rearrangements in cases with 3q and 1p cytogenetic abnormalities. EVI1 rearrangements were mainly associated with 3q26 cytogenetic abnormalities, but they have also been demonstrated in 6 cases (6/35;17,1%) without 3q26 cytogenetic involvement, because of complex mechanism and/or ‘cryptic‘ abnormalities. We have also identified new EVI1 rearrangements. Interestingly, two new similar translocations appeared in two brothers. Rearrangements, but also amplifications of PRDM16 resulting in gene overexpression, have often been associated with 1p36 aberrations. EVI1 and PRDM16 analyses have been performed in others cytogenetics subgroups, such as: -7/7q-, normal karyotype, and 3q abnormalities for PRDM16 and 1p for EVI1. EVI1 overexpression was frequent only in -7/7q- group (17.2%;10/58), and in one case was associated with amplification, not seen by CBA, because of metaphases’ poor quality. On the contrary, PRDM16 overexpression has been found in all cytogenetic subgroups, that we have considered. In some cases with complex karyotype, PRDM16 overexpression has been associated with gene amplification. FISH analysis and RQ-PCR have allowed us to identify EVI1 and PRDM16 abnormalities in patients with or without 3q26 and 1p36 abnormalities. Complex rearrangements or metaphases’ poor quality were the main reasons for the failed detection of these abnormalities in CBA. These observations indicate the importance of screening for EVI1 and PRDM16 abnormalities, especially in cases with 3q and 1p cytogenetic abnormalities, to identify at diagnosis patients with poor prognosis that could benefit from more aggressive chemotherapy and/or stem cell transplantation.
Baldazzi, Carmen <1980>. "Caratterizzazione Citogenetico-Molecolare delle alterazioni cromosomiche 3q26 e 1p36 nelle Sindromi Mieloproliferative." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2013. http://amsdottorato.unibo.it/5691/.
Full textEVI1 and PRDM16 overexpression has been associated with poor prognosis in myeloid malignancies. The main mechanism is the rearrangement of chromosome bands 3q26 and 1p36, where they are mapped, respectively. Overexpression has also been reported in specific cytogenetic subgroups, without 3q26 and 1p36 abnormalities observable by chromosome banding analysis (CBA). The main aim of this study has been to identify and characterize EVI1 and PRDM16 rearrangements in cases with 3q and 1p cytogenetic abnormalities. EVI1 rearrangements were mainly associated with 3q26 cytogenetic abnormalities, but they have also been demonstrated in 6 cases (6/35;17,1%) without 3q26 cytogenetic involvement, because of complex mechanism and/or ‘cryptic‘ abnormalities. We have also identified new EVI1 rearrangements. Interestingly, two new similar translocations appeared in two brothers. Rearrangements, but also amplifications of PRDM16 resulting in gene overexpression, have often been associated with 1p36 aberrations. EVI1 and PRDM16 analyses have been performed in others cytogenetics subgroups, such as: -7/7q-, normal karyotype, and 3q abnormalities for PRDM16 and 1p for EVI1. EVI1 overexpression was frequent only in -7/7q- group (17.2%;10/58), and in one case was associated with amplification, not seen by CBA, because of metaphases’ poor quality. On the contrary, PRDM16 overexpression has been found in all cytogenetic subgroups, that we have considered. In some cases with complex karyotype, PRDM16 overexpression has been associated with gene amplification. FISH analysis and RQ-PCR have allowed us to identify EVI1 and PRDM16 abnormalities in patients with or without 3q26 and 1p36 abnormalities. Complex rearrangements or metaphases’ poor quality were the main reasons for the failed detection of these abnormalities in CBA. These observations indicate the importance of screening for EVI1 and PRDM16 abnormalities, especially in cases with 3q and 1p cytogenetic abnormalities, to identify at diagnosis patients with poor prognosis that could benefit from more aggressive chemotherapy and/or stem cell transplantation.
MALLIA, SELENE. "La genomica su singola cellula rivela la gerarchia e l'architettura clonale nelle Neoplasie Mieloproliferative." Doctoral thesis, Università degli studi di Modena e Reggio Emilia, 2022. http://hdl.handle.net/11380/1278821.
Full textSomatic mutations in Hematopoietic Stem Cells (HSCs) cause Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis (PMF). PMF is a heterogeneous disorder consisting of bone marrow fibrosis, megakaryocyte hyperplasia and extramedullary hematopoiesis and is characterized by the worst prognosis among MPNs. About 15-20% of patients are unresponsive to conventional therapies and develop Acute Myeloid Leukemia (AML). In HSCs the main mutations, identified as “driver mutations” during MPNs pathogenesis, involve JAK2, CALR and MPL genes; in addition, many other genetic alterations contribute to the prognosis worsening and the development of AML. Disease progression and leukemic evolution in PMF results from an increase of the genomic complexity and clonal heterogeneity. Many studies confirmed that the mutational acquisition order affects the clinical outcome. However, the clonal architecture determining disease evolution and the clones guiding leukemic transformation are poorly understood. Recent studies demonstrate that single-cell (sc) genomics is a sensitive technique suitable to study clonal heterogeneity and to detect the evolution of the malignant cells in hematological neoplasms. For this reason, we used the sc-genomics approach to clarify the clonal complexity in PMF. Firstly, we developed a workflow for CD34+ Hematopoietic Stem Progenitor Cells (HSPCs) isolation from cord blood, fixation and immunostaining for CD34, in order to singularly separate the cells by DEP-array system (Menarini Silicon Biosystem) and to obtain a cell population suitable for sc-analysis. Then, we compared different whole genome amplification (WGA) protocols for single cells in order to obtain a uniform DNA amplification for Sanger sequencing and minimize allele drop out effect. Based on this method, we analyzed the CD34+ HSPCs of a PMF patient carrying JAK2V617F and other MPN frequent mutations. This patient was treated with JAK2-inhibitor Ruxolitinib but he was unresponsive to therapy and evolved to AML. In order to reconstruct the clonal hierarchy and architecture, we analyzed CD34+ cells during chronic phase (T1), the accelerated phase (T2) and the AML phase (T3). By means to sc-analysis, we established that TET2 was the first mutated gene, preceding JAK2 mutation, and this probably conferred a lower sensitivity to treatment. Moreover, we identified an increase of the allele burden of the TP53 mutation during disease progression, suggesting that TP53-mutated clones supported the accelerated (T2) phase. Interestingly, we already detected in T1 phase a small cell fraction, undetectable by bulk NGS and carrying the leukemogenic FLT3 mutation, probably driving the T3 phase. Finally, we characterized SRSF2 homozygous mutation that has not been described yet. Altogether our data demonstrate that sc-genomics is a promising method to uncover clonal heterogeneity in MPNs, highlighting the early occurrence of pro-leukemic mutations and to describe the real scenario of mutational events in hematological diseases.
GENOVESE, ELENA. "Ruolo di Calreticulina Wild-Type nell’emopoiesi fisiologica ed effetto delle mutazioni di Calreticulina nello sviluppo delle Neoplasie Mieloproliferative." Doctoral thesis, Università degli studi di Modena e Reggio Emilia, 2020. http://hdl.handle.net/11380/1199999.
Full textCalreticulin (CALR) is a 46 kDa endoplasmic reticulum (ER) chaperone responsible for intracellular calcium regulation and protein folding. CALR is also able to perform different functions outside the ER, such as responses to cellular stress. In 2013, several mutations were discovered in exon 9 of CALR gene in Myeloproliferative Neoplasms (MPNs); notably 36 different types of mutations have been reported in 60-80% of JAK2 and MPL unmutated Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) patients. These mutations consist of insertions or deletions that induce a frameshift, resulting in a loss of the C-terminal portion domain and the KDEL sequence. In this view, structural alterations of CALR protein might impair its functionality and its cellular localization. Indeed, recent data demonstrated that C-terminal of CALR mutants interacts with the thrombopoietin receptor (MPL), inducing the constitutive activation of JAK-STAT pathway. However, the precise mechanism of action through which CALR mutants contribute to the development of MPNs has only been partially clarified and there is no available information on the function of Wild-Type (WT) CALR during physiological hematopoiesis. In order to elucidate the biological role of WT CALR in the proliferation and differentiation of hematopoietic stem/progenitor cells (HPSCs), we performed gene silencing and overexpression experiments in human CD34+ cells. Our data demonstrated that WT CALR overexpression is able to enhance erythroid and megakaryocyte (MK) differentiation. Consistently, WT CALR silencing induces a marked repression of MK and erythroid lineages. In agreement with these results, gene expression profile (GEP) analysis confirmed that WT CALR is able to affect the expression of genes of erythroid and MK differentiation. Moreover, transcriptome analysis showed the modulation of several genes implicated in oxidative stress, ER stress response, DNA damage and in several pathways already described as able to play a role in MPN development. Next, to investigate the impact of CALR mutations in oxidative and ER stress response, we transduced K562 cells with vectors expressing one of the two commonest CALR mutated variants, either CALRdel52 or CALRins5. We chose to perform experiments in the K562 cell line, devoid of MPL expression, in order to identify additional pathways whose alterations might cooperate with cellular transformation mediated by MPL activation. Firstly, we demonstrated that CALR mutants reduce the capability to respond to ER stress and significantly decrease the activation of the pro-apoptotic unfolded protein response (UPR) pathway. Then, we showed that CALR mutations induce increased sensitivity to oxidative stress, also driving the accumulation of oxidative DNA damage. Finally, we studied the function of the antioxidant gene OXR1, found deregulated in GEP analysis. The downregulation of OXR1 affects the capability of mutant cells to counterbalance reactive oxygen species (ROS) accumulation, suggesting that lack of OXR1 expression might be one of the molecular mechanisms responsible for the impaired oxidative stress response mediated by mutant CALR. Altogether, our results suggest a new role of WT CALR in the regulation of erythroid and MK differentiation, whose deregulation is crucial in MPNs. Moreover, CALR mutants negatively impact on the ability to respond to ER stress, conferring apoptosis resistance to the cells. Finally, the impairment in oxidative stress response due to CALR mutations can lead to genomic instability, thus promoting cell transformation.
Pacquola, Enrica. "Correlazione tra "Non Responsività ad Aspirina" e stato mutazionale di JAK2 in pazienti con Neoplasie Mieloproliferative cromosoma Philadelfia negative (MPNs)." Doctoral thesis, Università degli studi di Padova, 2010. http://hdl.handle.net/11577/3421534.
Full textAbbiamo studiato 440 pazienti affetti da malattie mieloproliferative (PV ed ET), in particolare analizzando gli eventi trombotici avvenuti durante il trattamento con aspirina a basse dosi (100 mg/die). Abbiamo osservato che la presenza della mutazione del gene jak2 è significativamente correlato ad un elevato rischio trombotico.
Meireles, Catarina Filipa Amorim. "Doenças Mieloproliferativas." Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2009. http://hdl.handle.net/10216/52824.
Full textMeireles, Catarina Filipa Amorim. "Doenças Mieloproliferativas." Dissertação, Instituto de Ciências Biomédicas Abel Salazar, 2009. http://hdl.handle.net/10216/52824.
Full textAngona, Figueras Anna. "Caracterización de los progenitores hematopoyéticos CD34+ en las neoplasias mieloproliferativas y su papel en la evolución de la carga mutacional." Doctoral thesis, Universitat Autònoma de Barcelona, 2017. http://hdl.handle.net/10803/403818.
Full textMyeloproliferative neoplasms (MPN) are clonal diseases that origin from hematopoietic stem cell and are characterized by a proliferation of one or more of the myeloid cell types. According to the current WHO Classification, classic Philadelphia negative MPN include polycythemia vera (PV), essential thrombocythemia (TE) and primary mielofibrosis (PMF). In 2005, JAK2V617F mutation was described in 95% of PV patients and in half of ET and PMF patients. More recently, mutations affecting MPL or CALR gene have been reported in patients with JAK2V617F negative TE and PMF. All these mutations are considered driver mutations. In addition, other somatic mutations that do not act primarily on cell proliferation, but can modify the effect of the driver mutations, have been described. JAK2V617F MPN are characterized by the coexistence of normal and JAK2V617F-mutated progenitors. Knowledge of the mutational allele burden of JAK2V617F at the progenitor level could provide information on the biological basis of evolutionary clinical changes, especially myelofibrotic and acute leukemia transformation. Moreover, the mutational load at the progenitor level may also influence treatment response. Finally, some authors postulate that CALR mutated MPN are a distinct entity from a biological, clinical and prognostic point of view from JAK2V617F MPN. These observations could be the consequence of a different behaviour at the level of hematopoietic progenitors. In this sense, this work has characterized different subpopulations of hematopoietic progenitor cells (CD34+CD38- and CD34+CD38+) from patients with JAK2V617F and CALR-mutated MPN and their mutational allele burden has been correlated with disease status, presence of additional mutations and presence of clonal dominance. Also, we compared the mutational allele burden at the progenitor level according to the genotype (JAK2 or CALR). Finally, we evaluated the effect of the treatment with JAK2 inhibitors on the JAK2V617F mutant allele burden of the progenitor cells. In our first study, we showed that the percentage of CD34+ cells carrying JAK2V617F mutation increases during the evolution of the disease in PV patients. Moreover, we could demonstrate that the transformation to myelofibrosis is characterized by a predominance of JAK2V617F progenitor cells probably due to the expansion of homozygous clones. Finally, we observed that at the time of PV diagnosis there may be clonal hematopoiesis due to the expansion of clones with additional mutations. In the second study, we could show that the proportion of mutated hematopoietic progenitors is different according to the genotype. Patients with CALR-mutated MPN are characterized by an expansion of mutated progenitors, whereas patients with JAK2V617F ET and PV present a low percentage of mutated progenitors with a high differentiation capacity. Finally, we analysed the evolution of the mutational allele burden of JAK2V617F in 7 patients with MPN during the first 12 months of treatment with JAK2 inhibitor (Ruxolitinib). The results suggest that ruxolitinib has a minimal effect on the JAK2V617F mutant allele burden variation in CD34+ cells.
Moura, Lívia Gonzaga. "Expressão de Galectinas-1 e 3 em Neoplasias Mieloproliferativas." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/60/60135/tde-25022013-094107/.
Full textChronic myeloproliferative diseases are haematological malignant disorders characterized by the presence of an altered haematopoietic stem cell and independence or hypersensibility of their hematopoietic progenitors to cytokines. In 2008, WHO renamed this group of diseases as Myeloproliferative Neoplasms (MPN) in which is included Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). There have been advances concerning the knowledge about the mechanisms involved in MPN pathophysiology, however their pathogenesis remains unknow. Deregulation in apoptotic machinery seems to be involved in MPN pathophysiology. Fully understanding of apoptotic machinery and the influence of galectin-1 and 3 in this process in NMP patients might unveil novel targets for manipulation. The aims of the present study were to evaluate in leukocytes and CD34+ hematopoietic stem cells from PV, ET and PMF patients the LGALS1 and LGALS3 expression levels, the Galectin-3 plasma levels and to correlate LGALS1 and LGALS3 expression levels with galectin-3 plasma levels, apoptosis-related genes expression, JAK2 mutation status and clinic-laboratorial parameters. PV and PMF patients showed decreased expression levels of LGALS1 in CD34+ cells and also decreased LGALS1 expression levels in PMF leukocytes. ET patients presented an increased expression level of galectin-3 in leukocytes and plasma. We detected the correlations between LGALS3 gene expression with JAK2 allele burden and with leukocytes number in PV patients. We also observed in PMF patients the correlation between LGALS3 expression levels with JAK2 allele burden and spleen size. We also detected the correlation between LGALS1 expression levels BCL-2 gene expression in PV CD34+ HSC cells and between LGALS3 expression and A1, MCL-1, BAX and C-FLIP gene expression in TE leukocytes. Taken together, the results suggest the LGALS1and LGALS3 differential expression in NMP and the relation between JAK2V617F status with galectins expression, especially in PMF patients.
Book chapters on the topic "Mieloproliferative"
Prochwicz, Anna, and Dorota Krochmalczyk. "Impact of Interferon Alpha/Beta in the Management of Chronic Myeloproliferative Disorders." In Interferon - Immune Metabolism [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.104501.
Full text"Preliminares." In Neoplasias mieloproliferativas, I. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50001-5.
Full text"derechos de autor." In Neoplasias mieloproliferativas, II. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50002-7.
Full textAbecasis, Manuel, Alberto Álvarez Larrán, Rosa Ayala Díaz, Santiago Barrio, Beatriz Bellosillo, Luigi Gugliotta, Juan Carlos Hernández Boluda, et al. "Índice de autores." In Neoplasias mieloproliferativas, III—IV. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50003-9.
Full textBesses, Carles. "Presentación." In Neoplasias mieloproliferativas, VII. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50004-0.
Full textLópez, Joaquín Martínez, Santiago Barrio, and Rosa Ayala Díaz. "Patogenia de las neoplasias mieloproliferativas." In Neoplasias mieloproliferativas, 1–6. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50005-2.
Full textBellosillo, Beatriz. "Diagnóstico molecular de las neoplasias mieloproliferativas." In Neoplasias mieloproliferativas, 7–15. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50006-4.
Full textMartínez-Avilés, Luz M. "Biología molecular de la trombocitemia esencial negativa a JAK2." In Neoplasias mieloproliferativas, 17–25. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50007-6.
Full textSevilla, Julián. "Diagnóstico y tratamiento de la trombocitemia esencial en la edad pediátrica." In Neoplasias mieloproliferativas, 27–33. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50008-8.
Full textHonorato, Jesús. "Tratamientos aprobados para la trombocitemia esencial. Aspectos farmacológicos." In Neoplasias mieloproliferativas, 35–43. Elsevier, 2013. http://dx.doi.org/10.1016/b978-84-9022-648-3.50009-x.
Full textConference papers on the topic "Mieloproliferative"
De Oliveira, Beatriz Novelli, Ana Clara Benites Ciani De Carvalho Oliveira, Ana Flávia Lacotis, Camila Vedovato, and Viviany Oliveira Simão. "LEUCEMIA MIELOIDE CRÔNICA: TRATAMENTO E SEUS OBSTÁCULOS." In I Congresso Brasileiro de Imunologia On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/995.
Full textJesus, Anderson Avelino de, Samuel Santana Moura, Rebeca Santos Da Silva, Raqueline Pastor De Santana E. Santana, and Irlandia Oliveira Almeida. "LEUCEMIA MIELÓIDE CRÔNICA: O CROMOSSOMO PHILADELPHIA E O GENE BCR-ABL." In I Congresso Nacional Multidisciplinar de Oncologia On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/1529.
Full textBosso, Gabriela Jubilato, Letícia Cappellano, Luis Fernando Ventura Vilella, André Viu Matheus, and Ana Paula Pinto Batista. "LEUCEMIA MIELOIDE CRÔNICA EM ADOLESCENTE: RELATO DE CASO." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/28.
Full textSilva, Guilherme Ferreira Santos, and Marcelo José da Silva Magalhães. "TROMBOCITEMIA IDIOPÁTICA: ACHADOS DIAGNÓSTICOS E TRATAMENTO." In I Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/644.
Full textSoares, Vitória Moreira, Maria Clara Tomaz Feijão, Ana Carolina Filgueiras Teles, Emanuel Cintra Austregésilo Bezerra, and Aline Diogo Marinho. "NOVOS TRATAMENTOS DA LEUCEMIA NEUTROFÍLICA CRÔNICA: REVISÃO DE LITERATURA." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/119.
Full textCappellano, Letícia, Gabriela Jubilato Bosso, Luis Fernando Ventura Vilella, Gustavo Ribeiro Neves, and Luiza De Souza Santos Millare. "LEUCEMIA MIELOIDE CRÔNICA INFANTOJUVENIL: RELATO DE CASO." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/34.
Full textVilella, Luis Fernando Ventura, Gabriela Jubilato Bosso, Leticia Cappellano, Natalia Marques Rodrigues, and André Viu Matheus. "LEUCEMIA MIELOIDE CRÔNICA (LMC) EM ADOLESCENTE DE 13 ANOS: RELATO DE CASO." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/29.
Full textZeck, Suelen Camargo, Paloma Sabrina Ribeiro de Faria, Rodrigo Sippel Cruz, Tatiane Amorim Coelho, and Maria da Graça Bicalho. "TRANSPLANTE DE CÉLULAS-TRONCO HEMATOPOÉTICAS NA TROMBOCITEMIA ESSENCIAL." In I Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/614.
Full textTostes, Carine Pimenta Maurício Dantas, Kelly Costa De Almeida, Carolina V. A. Lutterbach De Carvalho, Gustavo Manso Fernandes, and Aislan Cristina R. F.Pascoal. "O EFEITO DA HIDROXIUREIA E MESILATO DE IMATINIBE NO TRATAMENTO DA LMC: RELATO DE CASO." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/14.
Full textFranco, Jéssyka Viana Valadares, Ana Paula Bezerra Barbosa, Carla Caroline Figueira De Oliveira, Gabriela Fernandes Ribeiro, and Letícia Clara Pires Campos. "TRANSPLANTE DE CÉLULAS- TRONCO HEMATOPOIÉTICA EM PACIENTES COM MIELOFIBROSE." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/74.
Full text